Due to the availability of targeted therapies, molecular testing of MET is now included in routine clinical workup in the NSCLC setting with comprehensive NGS panels including analysis for both exon 14 skipping mutations and MET amplifications (20). Here, MET is linked to non-small cell lung carcinoma.